Department of Cell Biology, Center for Cardiovascular Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Crit Care Med. 2010 Feb;38(2):562-71. doi: 10.1097/CCM.0b013e3181cb10b3.
To evaluate the effects of O-linked beta-N-acetylglucosamine (O-GlcNAc) levels on survival, inflammation, and organ damage 24 hrs after trauma-hemorrhage. We have previously shown that increasing protein O-GlcNAc levels by different mechanisms reduced inflammatory responses and improved organ function 2 hrs after trauma-hemorrhage.
Prospective, randomized, controlled study.
Animal research laboratory.
Male, adult Sprague-Dawley rats.
Overnight fasted animals were subjected to either sham surgery or trauma-hemorrhage and during the resuscitation phase received glucosamine (270 mg/kg) to increase O-GlcNAc synthesis or O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenyl carbamate (PUGNAc, 7 mg/kg) to inhibit O-GlcNAc removal, or mannitol as control.
Survival was followed up for 24 hrs. Surviving rats were euthanized and inflammatory responses, and end organ injuries were assessed. Both glucosamine and PUGNAc increased 24-hr survival compared with controls (control: 53%, GN: 85%, PUGNAc: 86%, log-rank test, p < .05). PUGNAc attenuated the trauma-hemorrhage-induced increase in serum interleukin-6 (sham surgery: 8 +/- 6, control: 181 +/- 36, PUGNAc: 42 +/- 22 pg/mL, p < .05), alanine transaminase (sham surgery: 95 +/- 14, control: 297 +/- 56, PUGNAc: 126 +/- 21 IU, p < .05), aspartate transaminase (sham surgery: 536 +/- 110, control: 1661 +/- 215, PUGNAc: 897 +/- 155 IU, p < .05), and lactate dehydrogenase (sham surgery: 160 +/- 18, control: 1499 +/- 311, PUGNAc: 357 +/- 99 IU, p < .05); however, glucosamine had no effect on these serum parameters. Furthermore, PUGNAc but not glucosamine maintained O-GlcNAc levels in liver and lung and significantly attenuated the NF-kappaB DNA activation in the liver. In the liver and heart, increased inducible nitric oxide synthase expression was also attenuated in the PUGNAc-treated group.
These results demonstrate that increasing O-GlcNAc with either glucosamine or PUGNAc improved 24-hr survival after trauma-hemorrhage. However, only PUGNAc treatment attenuated significantly the subsequent tissue injury and inflammatory responses, suggesting that inhibition of O-GlcNAc removal may represent a new therapeutic approach for the treatment of hypovolemic shock.
评估 O-连接的β-N-乙酰氨基葡萄糖(O-GlcNAc)水平对创伤性失血性休克后 24 小时的生存、炎症和器官损伤的影响。我们之前已经表明,通过不同的机制增加蛋白质 O-GlcNAc 水平可以降低炎症反应并改善器官功能,这一效果在创伤性失血性休克后 2 小时就已经出现。
前瞻性、随机、对照研究。
动物研究实验室。
雄性成年 Sprague-Dawley 大鼠。
过夜禁食的动物接受假手术或创伤性失血性休克,并在复苏阶段接受葡萄糖胺(270mg/kg)以增加 O-GlcNAc 合成或 O-(2-乙酰氨基-2-脱氧-D-葡萄糖基)氨基 N-苯甲酰胺(PUGNAc,7mg/kg)以抑制 O-GlcNAc 去除,或甘露醇作为对照。
对 24 小时的生存情况进行了跟踪。存活的大鼠被安乐死,并评估了炎症反应和终末器官损伤。与对照组相比,葡萄糖胺和 PUGNAc 均提高了 24 小时的生存率(对照组:53%,GN:85%,PUGNAc:86%,对数秩检验,p<0.05)。PUGNAc 减弱了创伤性失血性休克引起的血清白细胞介素-6(假手术:8±6,对照组:181±36,PUGNAc:42±22pg/ml,p<0.05)、丙氨酸转氨酶(假手术:95±14,对照组:297±56,PUGNAc:126±21IU,p<0.05)、天门冬氨酸转氨酶(假手术:536±110,对照组:1661±215,PUGNAc:897±155IU,p<0.05)和乳酸脱氢酶(假手术:160±18,对照组:1499±311,PUGNAc:357±99IU,p<0.05)的升高;然而,葡萄糖胺对这些血清参数没有影响。此外,PUGNAc 而不是葡萄糖胺维持了肝和肺中的 O-GlcNAc 水平,并显著减弱了肝中的 NF-κB DNA 激活。在肝和心脏中,诱导型一氧化氮合酶表达的增加也在 PUGNAc 治疗组中减弱。
这些结果表明,通过葡萄糖胺或 PUGNAc 增加 O-GlcNAc 可以提高创伤性失血性休克后 24 小时的生存率。然而,只有 PUGNAc 治疗显著减轻了随后的组织损伤和炎症反应,表明抑制 O-GlcNAc 去除可能是治疗低血容量性休克的一种新的治疗方法。